A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non-Germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy
Phase of Trial: Phase III
Latest Information Update: 28 Jan 2019
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms OPINION
- Sponsors AstraZeneca AB
- 11 Dec 2018 Planned number of patients changed from 265 to 250.
- 11 Dec 2018 Planned End Date changed from 17 Jul 2020 to 4 Jan 2021.
- 11 Dec 2018 Planned primary completion date changed from 17 Jul 2020 to 19 Jul 2020.